Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial
Javed Butler(Saint Luke's Health System), Imran Zainal Abidin(British Heart Foundation), Piotr Ponikowski(Wroclaw Medical University), Alessia Urbinati(Marche Polytechnic University), Stefano Corda(Université Paris Cité), G. Michael Felker(Clinical Research Institute), Eldrin F. Lewis(Brigham and Women's Hospital), Elias Tsougos(Henry Dunant Hospital), Laura Scelsi(Policlinico San Matteo Fondazione), Yogesh N.V. Reddy(Mayo Clinic), Ciaran J. McMullan(Harvard University), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Ferenc Lakatos, Aldo Edwin Rodriguez Escudero, Aguinaldo Figueiredo Freitas, Maria Borentain(Bayer (United States)), Luis Eduardo Echeverría, Vanja Vlajnic(Bayer (United States)), Robert J. Mentz(Duke University), Irina Barash(Merck & Co., Inc., Rahway, NJ, USA (United States)), Aleksander Żurakowski(American Heart of Poland), Kevin J. Anstrom(University of North Carolina at Chapel Hill), Adriaan A. Voors(University Medical Center Groningen), Lilin She(Clinical Research Institute), James E. Udelson(Tufts Medical Center), Hans Prozesky(Stellenbosch University), Trevor J. Gould(University of Minnesota), Marc P. Bonaca(The Medical Center of Aurora), Pedro Pinto Teixeira(Bayer (Germany)), JoAnn Lindenfeld(Vanderbilt University Medical Center), Alberto Cadena(University of the Coast), Carolyn Lam(National University of Singapore), Yüksel Çavuşoğlu(Eskişehir Osmangazi University), Giuseppe M.C. Rosano(Università degli studi di Cassino e del Lazio Meridionale), Mahesh J. Patel, Aiwen Xing(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michele Senni(British Heart Foundation), Christopher M. O’Connor(Inova Health System), Jose F. Kerr Saraiva, José Accini, Davis Gates(Merck & Co., Inc., Rahway, NJ, USA (United States)), Justin A. Ezekowitz(University of Alberta), Fabio Silveria, Ebrahim Noori
Cited by 77
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
|European Journal of Heart Failure|2016|5.9k